Inhibition of SIRT2 suppresses hepatic fibrosis

American Journal of Physiology - Gastrointestinal and Liver Physiology

Volumn 310, Issue 11, 2016, Pages G1155-G1168

  Arteaga, Maribel ^a   Shang, Na ^a   Ding, Xianzhong ^b   Yong, Sherri ^b   Cotler, Scott J ^b   Denning, Mitchell F ^a   Shimamura, Takashi ^a   Breslin, Peter ^a   Lüscher, Bernhard ^c   Qiu, Wei ^a  

^a LOYOLA UNIVERSITY CHICAGO   (United States)

^b LOYOLA UNIVERSITY CHICAGO   (United States)

^c RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

COL1A1; ECM; Hepatic stellate cell; Histone deacetylases; SMA

Indexed keywords

CARBON TETRACHLORIDE; HYDROLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MYC PROTEIN; SHORT HAIRPIN RNA; SIRTUIN 2; SIRTUIN 2 INHIBITOR; THIOACETAMIDE; UNCLASSIFIED DRUG; SIRT2 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; FEMALE; FIBROGENESIS; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER FIBROSIS; MALE; MOUSE; NONHUMAN; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; STELLATE CELL; ADULT; AGED; ANIMAL; C57BL MOUSE; CASE CONTROL STUDY; CELL LINE; GENETICS; HEPATIC STELLATE CELL; LIVER CIRRHOSIS; METABOLISM; MIDDLE AGED;

ADULT; AGED; ANIMALS; CARBON TETRACHLORIDE; CASE-CONTROL STUDIES; CELL LINE; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HEPATIC STELLATE CELLS; HUMANS; LIVER CIRRHOSIS; MALE; MICE; MICE, INBRED C57BL; MIDDLE AGED; PROTO-ONCOGENE PROTEINS C-MYC; SIRTUIN 2; THIOACETAMIDE;

EID: 84984622758     PISSN: 01931857     EISSN: 15221547     Source Type: Journal    
DOI: 10.1152/ajpgi.00271.2015     Document Type: Article

References (41)

1. Bataller R, Brenner DA. Hepatic stellate cells as a target for the treatment of liver fibrosis. Semin Liver Dis 21: 437–451, 2001.
2. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 115: 209–218, 2005.
3. Blomhoff R, Berg T. Isolation and cultivation of rat liver stellate cells. Methods Enzymol 190: 58–71, 1990.
4. Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La Vecchia C. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol 46: 827–839, 2007.
5. Cao W, Bao C, Padalko E, Lowenstein CJ. Acetylation of mitogenactivated protein kinase phosphatase-1 inhibits Toll-like receptor signaling. J Exp Med 205: 1491–1503, 2008.
6. Chen J, Chan AW, To KF, Chen W, Zhang Z, Ren J, Song C, Cheung YS, Lai PB, Cheng SH, Ng MH, Huang A, Ko BC. SIRT2 overexpression in hepatocellular carcinoma mediates epithelial to mesenchymal transition by protein kinase B/glycogen synthase kinase-3β/β-catenin signaling. Hepatology 57: 2013, 2287–2298.
7. Elsharkawy AM, Oakley F, Lin F, Packham G, Mann DA, Mann J. The NF-κB p50:p50:HDAC-1 repressor complex orchestrates transcriptional inhibition of multiple pro-inflammatory genes. J Hepatol 53: 519–527, 2010.
8. Friedman SL. Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 275: 2247–2250, 2000.
9. Griffiths C, Rooney C, Brock A. Leading causes of death in England and Wales–how should we group causes? Health Stat Q: 6–17, 2005.
10. Guo J, Loke J, Zheng F, Hong F, Yea S, Fukata M, Tarocchi M, Abar OT, Huang H, Sninsky JJ, Friedman SL. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 49: 960–968, 2009.
11. Hernandez-Gea V, Ghiassi-Nejad Z, Rozenfeld R, Gordon R, Fiel MI, Yue Z, Czaja MJ, Friedman SL. Autophagy releases lipid that promotes fibrogenesis by activated hepatic stellate cells in mice and in human tissues. Gastroenterology 142: 938–946, 2012.
12. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al. Histological grading and staging of chronic hepatitis. J Hepatol 22: 696–699, 1995.
13. Jing E, Gesta S, Kahn CR. SIRT2 regulates adipocyte differentiation through FoxO1 acetylation/deacetylation. Cell Metab 6: 105–114, 2007.
14. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med 10: 182–186, 2004.
15. Kim MJ, Kim DW, Park JH, Kim SJ, Lee CH, Yong JI, Ryu EJ, Cho SB, Yeo HJ, Hyeon J, Cho SW, Kim DS, Son O, Park J, Han KH, Cho YS, Eum WS, Choi SY. PEP-1-SIRT2 inhibits inflammatory response and oxidative stress-induced cell death via expression of antioxidant enzymes in murine macrophages. Free Radic Biol Med 63: 432–445, 2013.
16. Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol 25: 195–206, 2011.
17. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686–1690, 1995.
18. Liu PY, Xu N, Malyukova A, Scarlett CJ, Sun YT, Zhang XD, Ling D, Su SP, Nelson C, Chang DK, Koach J, Tee AE, Haber M, Norris MD, Toon C, Rooman I, Xue C, Cheung BB, Kumar S, Marshall GM, Biankin AV, Liu T. The histone deacetylase SIRT2 stabilizes Myc oncoproteins. Cell Death Differ 20: 503–514, 2013.
19. Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer 8: 976–990, 2008.
20. Mormone E, George J, Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem Biol Interact 193: 225–231, 2011.
21. Nevzorova YA, Hu W, Cubero FJ, Haas U, Freimuth J, Tacke F, Trautwein C, Liedtke C. Overexpression of c-myc in hepatocytes promotes activation of hepatic stellate cells and facilitates the onset of liver fibrosis. Biochim Biophys Acta 1832: 1765–1775, 2013.
22. North BJ, Marshall BL, Borra MT, Denu JM, Verdin E. The human Sir2 ortholog, SIRT2, is an NAD+-dependent tubulin deacetylase. Mol Cell 11: 437–444, 2003.
23. Outeiro TF, Kontopoulos E, Altmann SM, Kufareva I, Strathearn KE, Amore AM, Volk CB, Maxwell MM, Rochet JC, McLean PJ, Young AB, Abagyan R, Feany MB, Hyman BT, Kazantsev AG. Sirtuin 2 inhibitors rescue α-synuclein-mediated toxicity in models of Parkinson’s disease. Science 317: 516–519, 2007.
24. -Firzlaff J, Vervoorts J, Lasonder E, Kremmer E, Knoll B, Lüscher B. The regulation of SIRT2 function by cyclin-dependent kinases affects cell motility. J Cell Biol 180: 915–929, 2008.
25. Ponnusamy M, Zhou X, Yan Y, Tang J, Tolbert E, Zhao TC, Gong R, Zhuang S. Blocking sirtuin 1 and 2 inhibits renal interstitial fibroblast activation and attenuates renal interstitial fibrosis in obstructive nephropathy. J Pharmacol Exp Ther 350: 243–256, 2014.
26. Qin L, Han YP. Epigenetic repression of matrix metalloproteinases in myofibroblastic hepatic stellate cells through histone deacetylases 4: implication in tissue fibrosis. Am J Pathol 177: 1915–1928, 2010.
27. Qiu W, Wang X, Leibowitz B, Yang W, Zhang L, Yu J. PUMAmediated apoptosis drives chemical hepatocarcinogenesis in mice. Hepatology 54: 1249–1258, 2011.
28. Reddy GK, Enwemeka CS. A simplified method for the analysis of hydroxyproline in biological tissues. Clin Biochem 29: 225–229, 1996.
29. Ropero S, Esteller M. The role of histone deacetylases (HDACs) in human cancer. Mol Oncol 1: 19–25, 2007.
30. Rothgiesser KM, Erener S, Waibel S, Lüscher B, Hottiger MO. SIRT2 regulates NF-κB dependent gene expression through deacetylation of p65 Lys 310. J Cell Sci 123: 4251–4258, 2010.
31. Schuppan D, Kim YO. Evolving therapies for liver fibrosis. J Clin Invest 123: 1887–1901, 2013.
32. Schwer B, Verdin E. Conserved metabolic regulatory functions of sirtuins. Cell metabolism 7: 104–112, 2008.
33. Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle 3: 1133–1137, 2004.
34. Shang N, Arteaga M, Zaidi A, Stauffer J, Cotler SJ, Zeleznik-Le N, Zhang J, Qiu W. FAK is required for c-Met/α-catenin-driven hepatocarcinogenesis. Hepatology 61: 214–226, 2014
35. Shaul YD, Seger R. The MEK/ERK cascade: from signaling specificity to diverse functions. Biochim Biophys Acta 1773: 1213–1226, 2007.
36. Sundaresan NR, Pillai VB, Wolfgeher D, Samant S, Vasudevan P, Parekh V, Raghuraman H, Cunningham JM, Gupta M, Gupta MP. The deacetylase SIRT1 promotes membrane localization and activation of AKT and PDK1 during tumorigenesis and cardiac hypertrophy. Sci Signal 4: ra46, 2011.
37. Van Beneden K, Mannaerts I, Pauwels M, Van den Branden C, van Grunsven LA. HDAC inhibitors in experimental liver and kidney fibrosis. Fibrogenesis Tissue Repair 6: 1, 2013.
38. Vaquero A, Scher MB, Lee DH, Sutton A, Cheng HL, Alt FW, Serrano L, Sternglanz R, Reinberg D. SirT2 is a histone deacetylase with preference for histone H4 Lys 16 during mitosis. Genes Dev 20: 1256–1261, 2006.
39. Wu G, Song C, Lu H, Jia L, Yang G, Shi X, Sun S. Sirt2 induces C2C12 myoblasts proliferation by activation of the ERK1/2 pathway. Acta Biochim Biophys Sin 46: 342–345, 2014.
40. Xu L, Hui AY, Albanis E, Arthur MJ, O’Byrne SM, Blaner WS, Mukherjee P, Friedman SL, Eng FJ. Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis. Gut 54: 142–151, 2005.
41. Zhang Y, Au Q, Zhang M, Barber JR, Ng SC, Zhang B. Identification of a small molecule SIRT2 inhibitor with selective tumor cytotoxicity. Biochem Biophys Res Commun 386: 729–733, 2009.